Read by QxMD icon Read


Yi-Lun Wang, Hsiu-Huei Peng, Sheng-Yuan Su, Cheng-Tao Lin
OBJECTIVE: In advanced ovarian cancer, traditional therapy included debulking surgery and postoperative chemotherapy. We proposed immunochemotherapy (IMCT) combined with picibanil (OK-432), interleukin-2 (IL-2), and traditional platinum- and taxol-based chemotherapy as a better treatment option for advanced ovarian cancer. METHODS: We retrospectively reviewed the medical records of 51 patients with advanced ovarian cancer between 2007 and 2015 at Chang Gung Memorial Hospital Linkou Medical Center, including 26 patients who were treated with OK-432, IL-2, and platinum- and taxol-based chemotherapy (IMCT group) after debulking surgery; another 25 were treated with traditional platinum- and taxol-based chemotherapy (traditional chemotherapy group) after debulking surgery...
January 1, 2018: Reproductive Sciences
F Duan, X-L Su, Z-X Wei, D-W Kong, T-Y Huang, S Wang
OBJECTIVE: This study intended to explore the efficacy of computed tomography (CT)-guided implantation of iodine-125 (125I) seeds in the treatment of refractory malignant tumors with cancer pain and its influence on tumor markers in the serum. PATIENTS AND METHODS: 76 patients with refractory malignant tumors accompanied by cancer pain that received treatments in LongHua Hospital Shanghai University of Traditional Chinese Medicine from September 2013 to August 2014 were selected...
March 2018: European Review for Medical and Pharmacological Sciences
Usha Menon, Chloe Karpinskyj, Aleksandra Gentry-Maharaj
There has been much progress in ovarian cancer screening and prevention in recent years. Improved tools that combine genetic and epidemiologic factors to predict an individual's ovarian cancer risk are set to become available for tailoring preventive and screening approaches. The increasing evidence on tubal origins of a proportion of ovarian cancer has paved the way to use of opportunistic bilateral salpingectomy at tubal ligation and hysterectomy in the general population. Clinical trials are in progress to estimate the long-term effects on endocrine function...
April 6, 2018: Obstetrics and Gynecology
Na Han, Xun Sun, Chunxia Qin, Khamis Hassan Bakari, Zhijian Wu, Yongxue Zhang, Xiaoli Lan
OBJECTIVE: The purpose of this study is to investigate the value of 18 F-FDG PET/CT combined with assessment of tumor markers in serum or ascites for the diagnosing and determining the prognosis of benign and malignant ascites. MATERIALS AND METHODS: Patients with ascites of unknown cause who underwent evaluation with FDG PET/CT were included in this retrospective study. The maximum standardized uptake value (SUVmax ) and levels of the tumor markers carbohydrate antigen-125 (CA-125) and carcinoembryonic antigen (CEA) in serum and ascites were recorded...
April 9, 2018: AJR. American Journal of Roentgenology
Vesna S Antovska, Milka Trajanova, Iskra Krstevska, Irena Gosheva, Jasmina Chelebieva, Irina Prodanova
BACKGROUND: Ovarian strumal carcinoid is a germ cell tumour characterised by a mixture of thyroid tissue and carcinoid. Ovarian struma is a very rare occurrence with 0.3-1% incidence of all ovarian tumours and 3% of mature teratomas. Primary carcinoid ovarian tumours are still uncommon as a part of mature teratoma or mucinous cystadenoma. There are four major variants of a carcinoid tumour: insular, trabecular, strumal and mucinous. A strumal carcinoid is an unusual form of ovarian teratoma composed of an intimate admixture of thyroid/carcinoid tissues...
March 15, 2018: Open Access Macedonian Journal of Medical Sciences
Q Lin, S J Ding, T H Zhu, T T Li, X F Huang, X M Zhang
Objective: To determine the levels of coagulation and inflammatory factors in women with moderate and severe ovarian endometriosis so as to investigate the possible role of coagulation and inflammatory factors in the pathogenesis, diagnosis and treatment of this disease. Methods: From June 2015 and June 2017, clinical data of 366 patients with pathologically diagnosed moderate and severe ovarian endometriosis (case group) and 244 patients with pathologically diagnosed benign ovarian cysts (control group) in Women's Hospital of Zhejiang University School of Medicine were retrospectively analyzed...
March 25, 2018: Zhonghua Fu Chan Ke za Zhi
Xin Zheng, Shulin Chen, Linfang Li, Xiaohua Liu, Xiaomin Liu, Shuqin Dai, Peng Zhang, Huaiwu Lu, Zhongqiu Lin, Yuefei Yu, Guorong Li
OBJECTIVE: Serum human epididymis protein 4 (HE4) and transthyretin (TTR) are new markers for ovarian cancer. We compared HE4 and TTR with the gold marker CA-125 for the diagnosis of ovarian cancer patients. METHODS: 130 serum samples from benign ovarian tumor and 400 serum samples from healthy women were used to set up the cut-off. 126 serum samples from ovarian cancer patients before operation were collected to test the diagnostic value of these ELISA assays. The sensitivity, positive predictive value (PPV) and ROC curves were used to evaluate the diagnostic value...
March 30, 2018: Journal of Gynecology Obstetrics and Human Reproduction
Sotirios Tsiodras, Alina-Roxani Gouloumi, Zoi Tsakiraki, George Chrelias, Charalambos Chrelias, Stylianos Loukides, Ioannis Panayiotides
A rare case of ovarian sarcoidosis with peritoneal and omental involvement presenting as an ovarian malignancy is presented. Clinical, laboratory, and radiological evaluation of the patient revealed ascites and high levels of serum CA 125 and CA 15.3. The diagnosis of sarcoidosis was confirmed with pathology findings on tissues obtained during surgical laparotomy. Establishing the diagnosis of sarcoidosis can be treacherous and was complicated in this case by the falsely elevated biomarkers and ascites.
2018: Case Reports in Obstetrics and Gynecology
Emma Pérez, Katarzyna Bierla, Guillermo Grindlay, Joanna Szpunar, Juan Mora, Ryszard Lobinski
Lanthanide polymer-labelled antibodies were investigated to improve the analytical figures of merit of homogeneous immunoassays with inductively coupled plasma mass spectrometry (ICP-MS) detection for multiplexed biomarker analysis in human serum samples. Specific monoclonal antibodies against four cancer biomarkers (CEA, sErbB2, CA 15.3 and CA 125) were labelled with different polymer-based lanthanide group to increase the number of metal labels per binding site. After the immunoreaction of the biomarkers with the specific antibodies, antigen-antibody complexes were separated by size-exclusion chromatography followed by ICP-MS detection...
August 14, 2018: Analytica Chimica Acta
Anita Chudecka-Głaz, Aneta Cymbaluk-Płoska, Małgorzata Wężowska, Janusz Menkiszak
BACKGROUND: This study assessed the prognostic value of HE4 marker measurements at various stages of first-line chemotherapy for ovarian cancer. METHODS: The study consisted of 90 ovarian cancer patients, including 48 women undergoing primary surgical treatment and 42 patients qualified for neoadjuvant chemotherapy. Each patient underwent HE4 and CA 125 level measurements at the time of diagnosis and subsequently as follows: after surgical treatment, after the third course of adjuvant chemotherapy, before interval cytoreductive surgery and after chemotherapy...
2018: PloS One
Chanhee Han, Stefania Bellone, Eric R Siegel, Gary Altwerger, Gulden Menderes, Elena Bonazzoli, Tomomi Egawa-Takata, Francesca Pettinella, Anna Bianchi, Francesco Riccio, Luca Zammataro, Ghanshyam Yadav, Jarrod A Marto, Marie-France Penet, Douglas A Levine, Ronny Drapkin, Abhijit Patel, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Gloria S Huang, Masoud Azodi, Peter E Schwartz, Alessandro D Santin
INTRODUCTION: Since the majority of patients are diagnosed at an advanced stage, ovarian cancer remains the most lethal gynecologic malignancy. There is no single biomarker with the sensitivity and specificity required for effective cancer screening; therefore, we investigated a panel of novel biomarkers for the early detection of high-grade serous ovarian carcinoma. METHODS: Twelve serum biomarkers with high differential gene expression and validated antibodies were selected: IL-1Ra, IL-6, Dkk-1, uPA, E-CAD, ErbB2, SLPI, HE4, CA125, LCN2, MSLN, and OPN...
March 20, 2018: Gynecologic Oncology
Raluca Eftimie, Esraa Hassanein
BACKGROUND: Early cancer diagnosis is one of the most important challenges of cancer research, since in many cancers it can lead to cure for patients with early stage diseases. For epithelial ovarian cancer (which is the leading cause of death among gynaecologic malignancies) the classical detection approach is based on measurements of CA-125 biomarker. However, the poor sensitivity and specificity of this biomarker impacts the detection of early-stage cancers. METHODS: Here we use a computational approach to investigate the effect of combining multiple biomarkers for ovarian cancer (e...
March 20, 2018: Journal of Translational Medicine
Thais Fontes de Magalhães, Kathiane Lustosa Augusto, Livia Ponte Mota, Arthur Ribeiro da Costa, Rainardo Antonio Puster, Leonardo Robson Pinheiro Sobreira Bezerra
Endometriosis can have several different presentations, including overt ascites and peritonitis; increased awareness can improve diagnostic accuracy and patient outcomes. We aim to provide a systematic review and report a case of endometriosis with this unusual clinical presentation. The PubMed/MEDLINE database was systematically reviewed until October 2016. Women with histologically-proven endometriosis presenting with clinically significant ascites and/or frozen abdomen and/or encapsulating peritonitis were included; those with potentially confounding conditions were excluded...
March 19, 2018: Revista Brasileira de Ginecologia e Obstetrícia
Panya Sananpanichkul, Supanee Muangtan, Wineeya Suknikhom, Kornkarn Bhamarapravatana, Komsun Suwannarurk
Background: Endometriosis has a significant effect on many aspects of women’s lives, also increasing the risk of ovarian cancer. Although endometriosis is considered as a benign condition, it sometimes behaves like cancer. Methods: All medical records of epithelial ovarian cancer patients during January 2011 to December 2016 were reviewed. Recurrent cases were excluded. Data collected included age at diagnosis, parity, marital status, familial history of cancer, menopausal status, weight, height, smoking histroy, contraception, CA 125 level, result of surgery and pathological report...
February 26, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
Darian Volarić, Veljko Flego, Gordana Žauhar, Ljiljana Bulat-Kardum
Introduction: We investigated whether tumour markers carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 125 (CA-125), and cytokeratin 19 fragment (CYFRA 21-1) in pleural effusions and serum can be used to distinguish pleural effusion aetiology. Materials and methods: During the first thoracentesis, we measured pleural fluid and serum tumour marker concentrations and calculated the pleural fluid/serum ratio for patients diagnosed with pleural effusion, using electrochemiluminescence immunoassays...
February 15, 2018: Biochemia Medica: časopis Hrvatskoga Društva Medicinskih Biokemičara
Ben Davidson, Arild Holth, Zhihui Wang, Ellen Hellsylt, Claes G Tropé, Thea E Hetland Falkenthal, Ruth Holm
The objective of this study was to analyze the expression and clinical role of 14-3-3 family proteins in high-grade serous carcinoma (HGSC). Protein expression of 14-3-3 sigma (14-3-3σ) and 14-3-3 eta (14-3-3η) by immunohistochemistry was studied in 298 HGSC specimens (249 peritoneal, 49 pleural) and was analyzed for association with clinicopathologic parameters, chemoresponse and survival. The 14-3-3σ protein was diffusely (>75% of cells) expressed in 100% of carcinomas in analysis of a pilot series and was therefore not further analyzed...
February 21, 2018: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
Ching-Jung Lin, Teh-Fu Hsu, Yen-Hou Chang, Ben-Shian Huang, Ling-Yu Jiang, Peng-Hui Wang, Yi-Jen Chen
OBJECTIVE: To evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing the recurrence of postoperative adenomyosis-related symptoms. MATERIALS AND METHODS: From January 2005 through December 2014, a retrospective study including 133 patients with symptomatic adenomyosis undergoing conservative uterine-sparing surgery followed by gonadotropin-releasing hormone agonist treatment was conducted. We excluded the 18 patients who did not meet the inclusion criteria...
February 2018: Taiwanese Journal of Obstetrics & Gynecology
Jillian T Henderson, Elizabeth M Webber, George F Sawaya
Importance: Ovarian cancer is relatively rare but the fifth-leading cause of cancer mortality among United States women. Objective: To systematically review evidence on benefits and harms of ovarian cancer screening among average-risk women to inform the United States Preventive Services Task Force. Data Sources: MEDLINE, PubMed, Cochrane Collaboration Registry of Controlled Trials; studies published in English from January 1, 2003, through January 31, 2017; ongoing surveillance in targeted publications through November 22, 2017...
February 13, 2018: JAMA: the Journal of the American Medical Association
Zi-Hao Qi, Hua-Xiang Xu, Shi-Rong Zhang, Jin-Zhi Xu, Shuo Li, He-Li Gao, Wei Jin, Wen-Quan Wang, Chun-Tao Wu, Quan-Xing Ni, Xian-Jun Yu, Liang Liu
Pancreatic cancer is a lethal disease with a high metastatic potential. In our previous study, we identified a specific subgroup of patients with pancreatic cancer with a serum signature of carcinoembryonic antigen (CEA)+/cancer antigen (CA)125+/CA19-9 ≥1,000 U/ml. In this study, by using high-throughput screening analysis, we found that receptor-interacting protein kinases 4 (RIPK4) may be a key molecule involved in the high metastatic potential of this subgroup of patients with pancreatic cancer. A high RIPK4 expression predicted a poor prognosis and promoted pancreatic cancer cell migration and invasion via the RAF1/MEK/ERK pathway...
February 7, 2018: International Journal of Oncology
S Banerjee, A M Oza, M J Birrer, E P Hamilton, J Hasan, A Leary, K N Moore, B Mackowiak-Matejczyk, J Pikiel, I Ray-Coquard, P Trask, K Lin, E Schuth, A Vaze, Y Choi, J C Marsters, D J Maslyar, V Lemahieu, Y Wang, E W Humke, J F Liu
Background: Lifastuzumab vedotin (LIFA) is a humanized anti-NaPi2b monoclonal antibody conjugated to a potent anti-mitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. This study is the first to compare an antibody-drug-conjugate (ADC) to standard-of-care in ovarian cancer (OC) patients. Patients and Methods: Platinum-resistant OC patients were randomized to receive LIFA (2.4 mg/kg, intravenously, every 3 weeks [Q3W]), or pegylated liposomal doxorubicin (PLD) (40 mg/m2, intravenously, Q4W)...
February 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"